Arvinas presented Phase 1 biomarker data in Seoul on ARV-102, an oral compound that tags the LRRK2 protein for destruction by the cell's own disposal machinery rather than blocking its activity. In 24 people with Parkinson's dosed for 28 days, reductions in LRRK2 tracked with improved saccadic eye movements, lower cerebrospinal fluid markers of endolysosomal dysfunction and neuroinflammation, and higher markers of synaptic integrity. The trial was not designed to measure clinical benefit, and the sample remains small.
Key Points
- Oral LRRK2 degrader crossed the blood-brain barrier in patients
- Dose-dependent improvement in saccadic hypometria over 28 days
- CSF markers of neuroinflammation fell; synaptic integrity markers rose
Longevity Analysis
Targeted protein degradation reframes neurodegeneration as a clearance problem rather than an activity problem — removing the offending protein instead of inhibiting it, using the cell's existing disposal pathways. The accompanying shift in endolysosomal and inflammatory markers points to the same waste-handling and immune signaling machinery implicated across age-related brain decline, and the oculomotor readout offers an objective, clinician-independent signal that can be measured long before symptoms declare themselves. The clinical question remains open at 24 patients, but the logic of restoring cellular disposal capacity has relevance well beyond Parkinson's.
Original published by Longevity.Technology, by Kyle Umipig.